Paul Kelly Marcom, MD

Professor of Medicine
Member of the Duke Cancer Institute
Campus mail 10 Bryan Searle Drive, Room 461 Seeley G. Mudd Building, Durham, NC 27710
Phone (919) 684-3877
Email address

Basic Science:
-Germline and somatic genetic changes in breast cancer.

-Identification and management of individuals and families with hereditary cancer risk.
-Communication of cancer risk information to individuals and families.
-Breast cancer prevention.
-Optimizing management of early breast cancer.
-Treatment of metastatic breast cancer

Clinically, Dr. Marcom works as a medical oncologist in the multidisciplinary breast cancer clinic. He participates in clinical trials investigating new chemotherapeutic and biologic treatments. In addition, he is developing a new high risk, familial cancer clinic. This clinic will see patients and families thought to be at high risk of developing malignancies, and will interface with the forming Cancer Genetics Network. Patients and families will be counseled about their cancer risk, and identified for studying issues related to cancer genetics: determining penetrance of identified gene mutations, determining factors modifying genetic risk, prevention studies, etc. Finally, he also plans to be involved in clinical evaluation of drugs for treating breast cancer.

Areas of developing expertise include cell cycle alterations in malignancy, breast cancer, and hereditary cancer genetics.

Breast cancer, cell cycle, genetics, familial cancer, prognostic factors, angiogenesis

In Their Words

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1992 - 1995
  • Medical Resident, Medicine, Duke University, 1989 - 1992
  • M.D., Baylor University, 1989


Force, J, Howie, LJ, Abbott, SE, Bentley, R, Marcom, PK, Kimmick, G, Westbrook, K, Sammons, SL, Parks, M, Topping, DL, Emerson, R, Broadwater, G, Hyslop, T, Blackwell, KL, and Nair, SK. "Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype." Clinical Breast Cancer 18, no. 5 (October 2018): 410-417.

Full Text

McRee, AJ, Marcom, PK, Moore, DT, Zamboni, WC, Kornblum, ZA, Hu, Z, Phipps, R, Anders, CK, Reeder-Hayes, K, Carey, LA, Weck, KE, Perou, CM, and Dees, EC. "A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer." Clinical Breast Cancer 18, no. 4 (August 2018): 289-297.

Full Text

Saha, A, Harowicz, MR, Cain, EH, Hall, AH, Hwang, E-SS, Marks, JR, Marcom, PK, and Mazurowski, MA. "Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival." Breast Cancer Research and Treatment (July 10, 2018).

Full Text

Han, HS, Diéras, V, Robson, M, Palácová, M, Marcom, PK, Jager, A, Bondarenko, I, Citrin, D, Campone, M, Telli, ML, Domchek, SM, Friedlander, M, Kaufman, B, Garber, JE, Shparyk, Y, Chmielowska, E, Jakobsen, EH, Kaklamani, V, Gradishar, W, Ratajczak, CK, Nickner, C, Qin, Q, Qian, J, Shepherd, SP, Isakoff, SJ, and Puhalla, S. "Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study." Annals of Oncology : Official Journal of the European Society for Medical Oncology 29, no. 1 (January 2018): 154-161.

Full Text

Harowicz, MR, Saha, A, Grimm, LJ, Marcom, PK, Marks, JR, Hwang, ES, and Mazurowski, MA. "Can algorithmically assessed MRI features predict which patients with a preoperative diagnosis of ductal carcinoma in situ are upstaged to invasive breast cancer?." Journal of magnetic resonance imaging : JMRI 46, no. 5 (November 2017): 1332-1340.

Full Text

Marcom, PK. "Breast Cancer." In Genomic and Precision Medicine: Primary Care: Third Edition, 181-194. March 23, 2017.

Full Text

Buchanan, AH, Voils, CI, Schildkraut, JM, Fine, C, Horick, NK, Marcom, PK, Wiggins, K, and Skinner, CS. "Adherence to Recommended Risk Management among Unaffected Women with a BRCA Mutation." Journal of genetic counseling 26, no. 1 (February 2017): 79-92.

Full Text

Harowicz, MR, Robinson, TJ, Dinan, MA, Saha, A, Marks, JR, Marcom, PK, and Mazurowski, MA. "Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset." Breast Cancer Research and Treatment 162, no. 1 (February 2017): 1-10.

Full Text

Nelson, ER, Li, S, Kennedy, M, Payne, S, Kilibarda, K, Groth, J, Bowie, M, Parilla-Castellar, E, de Ridder, G, Marcom, PK, Lyes, M, Peterson, BL, Cook, M, Pizzo, SV, McDonnell, DP, and Bachelder, RE. "Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface." Oncotarget 7, no. 51 (December 2016): 84030-84042.

Full Text

Kamal, A, Zhang, T, Power, S, and Marcom, PK. "Is advanced imaging in early-stage breast cancer ever warranted? Reconciling clinical judgment with common quality measures." Jnccn Journal of the National Comprehensive Cancer Network 14, no. 8 (August 1, 2016): 993-998.

Full Text